A pivotal Phase 2 study of PRGN-2012 for the treatment of recurrent respiratory papillomatosis (RRP)
Latest Information Update: 14 May 2024
At a glance
- Drugs Zopapogene imadenovec (Primary)
- Indications Recurrent respiratory papillomatosis
- Focus Therapeutic Use
Most Recent Events
- 14 May 2024 New trial record
- 08 May 2024 According to Precigen media release, The Company will host a conference call on Monday, June 3, 2024 to discuss in detail the pivotal Phase 2 study data of PRGN-2012 for the treatment of recurrent respiratory papillomatosis (RRP) presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Additional details for the June 3rd conference call will be announced at a later date.